FATE Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
2.1M
+60.3%
1.3M
-5.1%
1.4M
-21.4%
1.7M
-8.7%
1.9M
Cost of Revenue
0
0
0
0
0
Gross Profit
2.1M
+60.3%
1.3M
-5.1%
1.4M
-21.4%
1.7M
-8.7%
1.9M
Operating Expenses
33.2M
-3.2%
34.3M
-5.0%
36.1M
-1.1%
36.5M
-6.2%
38.9M
R&D
24.4M
-1.3%
24.7M
-2.8%
25.4M
-1.6%
25.8M
-5.8%
27.4M
SG&A
8.8M
-8.0%
9.6M
-10.0%
10.7M
+0.3%
10.6M
-7.1%
11.4M
Operating Income
-31134000
+5.7%
-33000000
+5.0%
-34721000
+0.0%
-34735000
+6.0%
-36968000
EBITDA
-28354000
+5.7%
-30082000
+5.0%
-31658000
-0.5%
-31508000
+6.5%
-33690000
Net Income
-30159000
+3.4%
-31213000
+3.6%
-32374000
-0.4%
-32250000
+5.3%
-34070000
EPS (Basic)
$-0.25
+3.8%
$-0.26
+3.7%
$-0.27
+0.0%
$-0.27
+6.9%
$-0.29
EPS (Diluted)
$-0.25
+3.8%
$-0.26
+3.7%
$-0.27
+0.0%
$-0.27
+6.9%
$-0.29
Shares (Diluted)
120.4M
+0.3%
120.0M
+0.6%
119.3M
+0.2%
119.0M
+0.4%
118.5M
Fate Therapeutics (FATE) โ€” Financials